Aigen Investment Management LP Buys Shares of 15,231 Verve Therapeutics, Inc. (NASDAQ:VERV)

Aigen Investment Management LP bought a new stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 15,231 shares of the company’s stock, valued at approximately $74,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in shares of Verve Therapeutics by 908.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock valued at $38,000 after acquiring an additional 6,949 shares during the last quarter. Creative Planning acquired a new position in shares of Verve Therapeutics in the 3rd quarter valued at $50,000. PFG Investments LLC acquired a new position in shares of Verve Therapeutics in the 3rd quarter valued at $53,000. Daiwa Securities Group Inc. grew its holdings in shares of Verve Therapeutics by 89.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock valued at $59,000 after buying an additional 5,723 shares during the period. Finally, Cornercap Investment Counsel Inc. grew its holdings in shares of Verve Therapeutics by 13.5% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock valued at $73,000 after buying an additional 1,778 shares during the period. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Stock Performance

Shares of NASDAQ:VERV opened at $4.79 on Monday. Verve Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $19.34. The company has a market capitalization of $405.52 million, a P/E ratio of -1.95 and a beta of 1.75. The company has a 50-day simple moving average of $5.45 and a 200 day simple moving average of $5.67.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.11. The firm had revenue of $6.87 million during the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business’s revenue for the quarter was up 120.2% compared to the same quarter last year. During the same period last year, the business posted ($0.72) earnings per share. As a group, equities analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on VERV shares. HC Wainwright decreased their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group boosted their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.